Scholarlink

<p>Osteoarthritis (OA) is a prevalent degenerative joint disease affecting millions worldwide, characterized by cartilage degradation and joint inflammation. Current treatments primarily alleviate symptoms but fail to halt disease progression, underscoring the need for disease-modifying therapies. This study explored the repurposing of bicalutamide, a selective androgen receptor antagonist used in prostate cancer, as a potential MMP-13 inhibitor to target cartilage degradation in OA. Using molecular docking, 250-nanosecond molecular dynamics simulations, MM-PBSA binding energy calculations, and ADMET profiling, we compared bicalutamide against diacerein and BI-4394 using validated MMP-13 structure (PDB: 5BPA). Bicalutamide demonstrated moderate binding affinity (docking score: -5.06) with favourable MM-PBSA energy (-45.148 ± 1.512&#xa0;kJ/mol). Remarkably, molecular dynamics revealed bicalutamide induced the greatest MMP-13 structural stabilization, exhibiting lowest protein RMSD (0.384 ± 0.046&#xa0;nm) and RMSF values (0.137 ± 0.112&#xa0;nm). ADMET analysis showed bicalutamide’s advantage as non-CYP450 3A4 substrate, reducing drug-drug interaction risks. This first computational study elucidated a unique, structure-stabilizing mechanism by which bicalutamide inhibited MMP-13, representing a notable departure from conventional competitive inhibitors. Collectively, these findings supported bicalutamide’s potential as a disease-modifying therapeutic for osteoarthritis and strongly warranted further experimental validation to advance its clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing bicalutamide as a potential inhibitor of MMP13 for osteoarthritis treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月28日

查看全文
  • Gladson David Masih,
  • Rahul Soloman Singh,
  • Ashutosh Singh,
  • Gitika Batra,
  • Benjamin Suroy,
  • Gajendra Choudhary,
  • Shiv Charan,
  • Vikas Bachhal,
  • Ajay Prakash,
  • Bikash Medhi

摘要

Osteoarthritis (OA) is a prevalent degenerative joint disease affecting millions worldwide, characterized by cartilage degradation and joint inflammation. Current treatments primarily alleviate symptoms but fail to halt disease progression, underscoring the need for disease-modifying therapies. This study explored the repurposing of bicalutamide, a selective androgen receptor antagonist used in prostate cancer, as a potential MMP-13 inhibitor to target cartilage degradation in OA. Using molecular docking, 250-nanosecond molecular dynamics simulations, MM-PBSA binding energy calculations, and ADMET profiling, we compared bicalutamide against diacerein and BI-4394 using validated MMP-13 structure (PDB: 5BPA). Bicalutamide demonstrated moderate binding affinity (docking score: -5.06) with favourable MM-PBSA energy (-45.148 ± 1.512 kJ/mol). Remarkably, molecular dynamics revealed bicalutamide induced the greatest MMP-13 structural stabilization, exhibiting lowest protein RMSD (0.384 ± 0.046 nm) and RMSF values (0.137 ± 0.112 nm). ADMET analysis showed bicalutamide’s advantage as non-CYP450 3A4 substrate, reducing drug-drug interaction risks. This first computational study elucidated a unique, structure-stabilizing mechanism by which bicalutamide inhibited MMP-13, representing a notable departure from conventional competitive inhibitors. Collectively, these findings supported bicalutamide’s potential as a disease-modifying therapeutic for osteoarthritis and strongly warranted further experimental validation to advance its clinical application.